Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Ludwig-Maximilians - University of Munich.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:
NCT00406900
First received: November 29, 2006
Last updated: December 5, 2006
Last verified: November 2006
  Purpose

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients


Condition Intervention
Melanoma
Radiotherapy
Metastatic Disease
Procedure: Treatment of metastatic disease

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by Ludwig-Maximilians - University of Munich:

Estimated Enrollment: 560
Study Start Date: January 1999
Estimated Study Completion Date: September 2006
Detailed Description:

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • uveal melanoma (With/without overt metastatic disease)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406900

Contacts
Contact: Ulrich C Schaller, MD +49/89/5160 ext 3811 ulrich.schaller@med.uni-muenchen.de

Locations
Germany
Dept of Ophthalmology, University of Munich Recruiting
Munich, Germany, 80538
Contact: Ulrich C Schaller, MD    +49895160 ext 3811    ulrich.schaller@med.uni-muenchen.de   
Principal Investigator: Ulrich C Schaller, MD         
Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
Investigators
Principal Investigator: Ulrich C Schaller, MD University of Munich, Germany
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00406900     History of Changes
Other Study ID Numbers: MIA
Study First Received: November 29, 2006
Last Updated: December 5, 2006
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Ludwig-Maximilians - University of Munich:
uveal melanoma
metastatic disease

Additional relevant MeSH terms:
Melanoma
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pathologic Processes

ClinicalTrials.gov processed this record on October 21, 2014